Japan's Taisho Struggles Overseas In Q1 As Domestic Sales Recover
Japan's Taisho posted OTC sales down 5% its first quarter, as turnover fell double-digits in its Europe and Americas region due to the ongoing impact of the COVID-19 pandemic.
You may also be interested in...
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
UK consumer healthcare industry association PAGB has joined forces with a number of like-minded groups to call on the government to implement a national strategy for self-care to help relieve pressure on the NHS.
Is your company in the running to win an OTC Marketing Award on 1 December?